Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability and preliminary efficacy of
vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours
and less than 6 months duration